Literature DB >> 24568917

[Impact of continuous blood purification on T cell subsets in children with severe sepsis].

Yuan-Hong Yuan1, Yuan-Hong Yuan1, Zheng-Hui Xiao, Hui Zhang, Jiang-Hua Fan, Xin-Ping Zhang, Xiu-Lan Lu, Zhi-Yue Xu, Hai-Yan Luo.   

Abstract

OBJECTIVE: To investigate the impact of continuous blood purification (CBP) on T-cell subsets and prognosis in children with severe sepsis.
METHODS: A total of 42 children with severe sepsis were randomly divided into a control group (n=22) and a CBP group (n=20). The patients in the control group received conventional treatment, while those in the CBP group underwent continuous veno-venous hemofiltration daily 12-24 hours for 3 days besides conventional treatment. Changes in clinical variables and in peripheral blood regulatory T cell subsets were assessed 3 and 7 days after treatment.
RESULTS: The pediatric intensive care unit length of stay and duration of mechanical ventilation were significantly shortened and the 28-day mortality rate was significantly lower in the CPB treatment group as compared with the control group (P<0.05). In the CBP treatment group, the percentage of CD3(+), CD4(+), CD8(+) T cell populations and PCIS scores were significantly higher at 3 and 7 days after treatment than before treatment (P<0.05). At 7 days after treatment, the percentage of CD3(+), CD4(+), CD8(+) T cell populations, CD4(+)/CD8(+) ratio and PCIS scores were significantly higher in the CBP group than in the control group (P<0.05).
CONCLUSIONS: The CBP treatment may counteract the suppression of immune function and thus improve prognosis in children with severe sepsis.

Entities:  

Mesh:

Year:  2014        PMID: 24568917

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  1 in total

1.  Global Case-Fatality Rates in Pediatric Severe Sepsis and Septic Shock: A Systematic Review and Meta-analysis.

Authors:  Bobby Tan; Judith Ju-Ming Wong; Rehena Sultana; Janine Cynthia Jia Wen Koh; Mark Jit; Yee Hui Mok; Jan Hau Lee
Journal:  JAMA Pediatr       Date:  2019-04-01       Impact factor: 16.193

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.